Somatostatin analogues
CA 2039880 A1 · Owner: Cai, Ren Z. · Inventors: Cai, Ren Z.; Schally, Andrew V.; Janaky, Tamas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
900312 RV6 SHAL3.0-007, ABSTRACT OF THE DISCLOSURE There are disclosed two, cytotoxic, structurally closely related groups of compounds, namely compounds of the formula: wherein R1 is L or D-Phe, D-Trp, L or D-Mel R3 is Mel, Tyr or Phe, R6 is Thr or Val R8 is Thr, Trp or Mel, Q is selected from the group consisting of hydrogen L and D-Mel, Mel-Mel, dipeptide, cyclopropanealkanoyl aziridine-2-carbonyl, methotrexoyl, 1,4naphthoquinone-5-oxycarbonylethyl, epoxyalkyl and the n-carbonyl-alkylamino derivatives thereof; and the n-carbonyl-alkanoyl derivatives of 2-hydroxymethyl-anthraquinone doxorubicin, esperamycin, and mitomycin C; wherein the ncarbonyl-alkylamino group has the formula …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 5, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 5, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 5, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.